medwireNews: The Scottish Medicines Consortium (SMC) has accepted the use of carfilzomib in Scottish NHS patients with relapsed or refractory multiple myeloma who have received between one and three prior therapies.
The advisory is issued on the basis of the phase III ENDEAVOR trial results showing improved progression-free survival with carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone as well as longer overall survival.
However, the SMC advice is based on the continuation of the Patient Access Scheme’s provision of carfilzomib at a cost effective amount.
The announcement follows the UK’s National Institute for Health and Care Excellence’s recent recommendation for use of the irreversible proteasome inhibitor, given in combination with dexamethasone with or without lenalidomide, in England and Wales.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group